New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis

Patrys is a publicly-listed company company focused on developing novel antibody technologies for cancer and NETosis-driven inflammatory diseases

Get news and updates from Patrys delivered to your inbox.

Keep up to date with the latest news from Patrys by following us on social media.

Menu